Insulin sensitivity across the lifespan from obese adolescents to obese adults with impaired glucose tolerance: Who is worse off?

Pediatric Diabetes

Volumn 19, Issue 2, 2018, Pages 205-211

  Arslanian, Silva ^a   Kim, Joon Young ^a   Nasr, Alexis ^a   Bacha, Fida ^b   Tfayli, Hala ^c   Lee, SoJung ^a   Toledo, Frederico G S ^d  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

adults; clamp; impaired glucose tolerance; insulin sensitivity; youth

Indexed keywords

GLUCOSE; INSULIN SENSITIZING AGENT;

ADOLESCENCE; ADOLESCENT; ADULT; ADULTHOOD; ARTICLE; BODY COMPOSITION; BODY FAT; CHILD; CONTROLLED STUDY; DETERIORATION; DRUG RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; LIFESPAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ONSET AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; AGING; BODY MASS; CHILDHOOD OBESITY; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; DISEASE EXACERBATION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PENNSYLVANIA; PROOF OF CONCEPT; RISK; SEVERITY OF ILLNESS INDEX;

ADIPOSITY; ADOLESCENT; ADULT; AGING; BODY MASS INDEX; CHILD; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INTOLERANCE; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; PEDIATRIC OBESITY; PENNSYLVANIA; PROOF OF CONCEPT STUDY; RETROSPECTIVE STUDIES; RISK; SEVERITY OF ILLNESS INDEX;

EID: 85041946806     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12562     Document Type: Article

References (40)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549-1555.
2. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: United States. NCHS Data Brief. 2011–2014;2015:1-8.
3. Dabelea D, Bell RA, D'Agostino RB Jr, et al; Writing Group for the SEARCH for Diabetes in Youth Study Group. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716-2724.
4. Li C, Ford ES, Zhao G, Mokdad AH. Prevalence of pre-diabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among U.S. adolescents: National Health and Nutrition Examination Survey 2005–2006. Diabetes Care. 2009;32:342-347.
5. Dabelea D, Mayer-Davis EJ, Saydah S, et al; Writing Group for the SEARCH for Diabetes in Youth Study Group. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311:1778-1786.
6. Hannon TS, Arslanian SA. The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci. 2015;1353:113-137.
7. Lynch J, El Ghormli L, Fisher L, et al; TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1735-1741.
8. Weinstock RS, Caprio S, Copeland KC, et al; TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1758-1764.
9. Levitsky LL, Danis RP, Drews KL, et al; TODAY Study Group. Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. Diabetes Care. 2013;36:1772-1774.
10. Zeitler P, Hirst K, Pyle L, et al; TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247-2256.
11. Dart AB, Martens PJ, Rigatto C, Brownell MD, Dean HJ, Sellers EA. Earlier onset of complications in youth with type 2 diabetes. Diabetes Care. 2014;37:436-443.
12. Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013;36:3863-3869.
13. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
14. Rascati K, Richards K, Lopez D, Cheng LI, Wilson J. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database. Diabetes Obes Metab. 2013;15:901-905.
15. Arslanian S, Pyle L, Payan M, et al; TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and beta-cell function in TODAY. Diabetes Care. 2013;36:1749-1757.
16. Kahn SE, Lachin JM, Zinman B, et al; ADOPT Study Group. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes. 2011;60:1552-1560.
17. Linder K, Springer F, Machann J, et al. Relationships of body composition and liver fat content with insulin resistance in obesity-matched adolescents and adults. Obesity. 2014;22:1325-1331.
18. Gidding SS, Keith SW, Falkner B. Adolescent and adult African Americans have similar metabolic dyslipidemia. J Clin Lipidol. 2015;9:368-376.
19. George L, Bacha F, Lee S, Tfayli H, Andreatta E, Arslanian S. Surrogate estimates of insulin sensitivity in obese youth along the spectrum of glucose tolerance from normal to prediabetes to diabetes. J Clin Endocrinol Metab. 2011;96:2136-2145.
20. Sjaarda LA, Michaliszyn SF, Lee S, et al. HbA(1c) diagnostic categories and beta-cell function relative to insulin sensitivity in overweight/obese adolescents. Diabetes Care. 2012;35:2559-2563.
21. Toledo FG, Menshikova EV, Ritov VB, et al. Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. Diabetes. 2007;56:2142-2147.
22. Tanner JM. Growth and maturation during adolescence. Nutr Rev. 1981;39:43-55.
23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Suppl 1):S81-S90.
24. Bacha F, Gungor N, Lee S, Arslanian SA. In vivo insulin sensitivity and secretion in obese youth: what are the differences between normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes? Diabetes Care. 2009;32:100-105.
25. Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab. 2001;86:66-71.
26. Miyazaki Y, Glass L, Triplitt C, Wajcberg E, Mandarino LJ, DeFronzo RA. Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2002;283:E1135-E1143.
27. Groop LC, Bonadonna RC, DelPrato S, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest. 1989;84:205-213.
28. Bizzotto R, Natali A, Gastaldelli A, et al. Glucose uptake saturation explains glucose kinetics profiles measured by different tests. Am J Physiol Endocrinol Metab. 2016;311:E346-E357.
29. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402-2410.
30. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
31. Bacha F, Gungor N, Lee S, Arslanian SA. Progressive deterioration of beta-cell function in obese youth with type 2 diabetes. Pediatr Diabetes. 2013;14:106-111.
32. Moran A, Jacobs DR Jr, Steinberger J, et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes. 1999;48:2039-2044.
33. Hannon TS, Janosky J, Arslanian SA. Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. Pediatr Res. 2006;60:759-763.
34. Ferrannini E, Vichi S, Beck-Nielsen H, Laakso M, Paolisso G, Smith U. Insulin action and age. European Group for the Study of Insulin Resistance (EGIR). Diabetes. 1996;45:947-953.
35. Basu R, Breda E, Oberg AL, et al. Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes. 2003;52:1738-1748.
36. Drew BG, Rye KA, Duffy SJ, Barter P, Kingwell BA. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol. 2012;8:237-245.
37. Liu HH, Li JJ. Aging and dyslipidemia: a review of potential mechanisms. Ageing Res Rev. 2015;19:43-52.
38. Reaven GM, Chen YD. Role of abnormal free fatty acid metabolism in the development of non-insulin-dependent diabetes mellitus. Am J Med. 1988;85:106-112.
39. Michaliszyn SF, Mari A, Lee S, et al. Beta-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes. 2014;63:3846-3855.
40. Singal P, Muniyappa R, Chisholm R, et al. Simple modeling allows prediction of steady-state glucose disposal rate from early data in hyperinsulinemic glucose clamps. Am J Physiol Endocrinol Metab. 2010;298:E229-E236.